Free Trial
NASDAQ:LENZ

LENZ Therapeutics (LENZ) Stock Price, News & Analysis

LENZ Therapeutics logo
$34.82 +3.46 (+11.03%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$34.93 +0.11 (+0.31%)
As of 09:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About LENZ Therapeutics Stock (NASDAQ:LENZ)

Key Stats

Today's Range
$31.01
$34.94
50-Day Range
$25.34
$34.82
52-Week Range
$16.54
$38.93
Volume
383,797 shs
Average Volume
191,199 shs
Market Capitalization
$980.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.60
Consensus Rating
Buy

Company Overview

LENZ Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
20th Percentile Overall Score

LENZ MarketRank™: 

LENZ Therapeutics scored higher than 20% of companies evaluated by MarketBeat, and ranked 825th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    LENZ Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    LENZ Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about LENZ Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for LENZ Therapeutics are expected to decrease in the coming year, from ($2.18) to ($2.58) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of LENZ Therapeutics is -19.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of LENZ Therapeutics is -19.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    LENZ Therapeutics has a P/B Ratio of 4.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about LENZ Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    15.60% of the float of LENZ Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LENZ Therapeutics has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in LENZ Therapeutics has recently increased by 2.10%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    LENZ Therapeutics does not currently pay a dividend.

  • Dividend Growth

    LENZ Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.60% of the float of LENZ Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LENZ Therapeutics has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in LENZ Therapeutics has recently increased by 2.10%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for LENZ Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    3 people have searched for LENZ on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.90% of the stock of LENZ Therapeutics is held by insiders.

  • Percentage Held by Institutions

    54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about LENZ Therapeutics' insider trading history.
Receive LENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LENZ Stock News Headlines

Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
LENZ Therapeutics Inc Dividends - Morningstar
LENZ Therapeutics Inc Financials - Morningstar
LENZ Therapeutics: Ready To Test Its Potential
See More Headlines

LENZ Stock Analysis - Frequently Asked Questions

LENZ Therapeutics' stock was trading at $28.87 at the beginning of 2025. Since then, LENZ stock has increased by 20.6% and is now trading at $34.82.

LENZ Therapeutics, Inc. (NASDAQ:LENZ) announced its quarterly earnings data on Wednesday, May, 7th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.02.
Read the conference call transcript
.

Top institutional investors of LENZ Therapeutics include Harbor Capital Advisors Inc. (0.18%). Insiders that own company stock include Ra Capital Management, LP and James W Mccollum.
View institutional ownership trends
.

Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that LENZ Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
5/07/2025
Today
7/10/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LENZ
Previous Symbol
NASDAQ:LENZ
CIK
1815776
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

High Price Target
$60.00
Low Price Target
$37.00
Potential Upside/Downside
+33.8%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$49.77 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$7.42 per share
Price / Book
4.69

Miscellaneous

Free Float
26,204,000
Market Cap
$980.18 million
Optionable
N/A
Beta
0.42
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:LENZ) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners